Congestive Heart Failure

Clinical Trials

Below is a list of Congestive Heart Failure clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Genetic Basis of Left Ventricular Recovery in Congestive Heart Failure
Research suggests that many cases of cardiomyopathy are caused initially by a virus, which then causes the body's immune system to attack the heart. This is an inflammatory
reaction which leads to heart damage. In some patients with this disorder, the heart will recover significantly over the first year, while others will be left with a chronically weak heart. The purpose of this research study is to determine if persons who present with the recent onset of primary cardiomyopathy have a better chance of recovery if they have certain genes and for a stronger inflammatory reaction.
Read more

Heart Failure and Control Trial Investigating Outcomes of Exercise Training
Mayo Clinic's Cardiovascular Research Program is conducting a research study involving patients who have congestive heart failure. This study is being done to determine if a long-term exercise program affects illness and survival.

Read more

Heart Failure and Control Trial Investigating Outcomes of Exercise Training
Mayo Clinic's Cardiovascular Research Program is conducting a research study involving patients who have congestive heart failure. This study is being done to determine if a long-term exercise program affects illness and survival.
Read more

TOPCAT
Subjects with heart failure are asked to volunteer in this study. The purpose for this study is to see if adding a drug called spironolactone to the current treatment for heart failure is able to safely improve heart failure. The study aims to examine the safely and effectiveness of spironolactone compared with placebo, which is an inactive drug that serves as pretend treatment (with no active drug in it), in the treatment of adults with heart failure and a certain level of heart contraction. Spironolactone is approved by the Food and Drug Administration (FDA) for the treatment of congestive heart failure. However, this study uses a lower starting dosage of spironolactone that is not approved by the FDA and compares it to placebo to test if the drug has a real effect.
Read more

We are testing the safety and effectiveness of sildenafil (Viagra) to placebo (a pill containing no medication) in patients with diastolic heart failure.
The purpose of this study is to compare the safety and effectiveness of sildenafil (Viagra) to a placebo (a pill containing no medication) in patients with diastolic heart failure to see if it will improve your ability to exercise and your quality of life. You will be asked to take this study medication for 6 months.
Read more